Blue Jet Healthcare Ltd (NSE: BLUEJET, BSE: 544009) is a Thane, Maharashtra-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹9,855 Cr, it ranks #589 by market cap among the 6,137 Indian listed companies on FinBizNet, and #9 of 11 in Pharmaceutical CDMO and CRO Services. At ₹475.55 (as of 25 Oct 2026), the share price is 30.9% below its 52-week high of ₹688.50 and 46.3% above its 52-week low of ₹325.00. The share price is down 29.2% over one year and down 16.1% over three months.
| Current Price | ₹475.55 |
|---|---|
| Market Cap | ₹9,855 Cr |
| NSE Symbol | BLUEJET |
| BSE Code | 544009 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 35.5 |
| Return on Equity | 19.88% |
| Return on Assets | 11.24% |
| 52-Week Range | ₹325.00 – ₹688.50 |
| 1-Year Price Change | -29.2% |
| 3-Month Price Change | -16.1% |
| Beta (1Y) | 0.85 |
| Dividend Yield | 0.24% |
| Headquarters | Thane, Maharashtra |
| Website | www.bluejethealthcare.com |
| Revenue | ₹293 Cr |
|---|---|
| Net Profit | ₹78 Cr |
| Net Margin | 26.7% |
| EPS (Basic) | ₹4.51 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
1. Generic Formulation Business-This segment engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. It also engages in contract manufacturing business.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹2,42,758 Cr | 93.8 | 16.19% | ₹3,080 Cr | +35.6% |
| Anthem Biosciences Limited | ₹46,303 Cr | 77.5 | 19.45% | ₹418 Cr | +5.3% |
| Sai Life Sciences Limited | ₹29,513 Cr | 85 | 15.13% | ₹554 Cr | +58.5% |
| Cohance Lifesciences Ltd | ₹17,754 Cr | 97.9 | 5.11% | ₹422 Cr | -49.9% |
| Onesource Specialty Pharma Limited | ₹16,144 Cr | -213 | -1.26% | ₹449 Cr | -27.8% |
| Syngene International Ltd. | ₹15,371 Cr | 50.6 | 6.62% | ₹736 Cr | -42.7% |
| Jubilant Pharmova Ltd | ₹14,958 Cr | 37.3 | 5.96% | ₹2,229 Cr | -12.8% |
| Concord Biotech Ltd | ₹14,008 Cr | 51.7 | 13.54% | ₹257 Cr | -19.5% |
| Blue Jet Healthcare Ltd | ₹9,855 Cr | 35.5 | 19.88% | ₹293 Cr | -29.2% |
Listed by market capitalisation. Ratios are shown for context only.
Blue Jet Healthcare Ltd is trading at ₹475.55, with a market capitalisation of ₹9,855 Cr.
Blue Jet Healthcare Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Blue Jet Healthcare Ltd has a P/E of 35.5 and a return on equity of 19.88%.
Blue Jet Healthcare Ltd is listed on the NSE under the symbol BLUEJET and on the BSE under the scrip code 544009.
Blue Jet Healthcare Ltd's share price is down 29.2% over one year and down 16.1% over three months. Its 52-week range is ₹325.00 to ₹688.50.
In Q1 FY27, Blue Jet Healthcare Ltd reported revenue of ₹293 Cr and net profit of ₹78 Cr, with basic EPS of ₹4.51 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.